Van Trung Chu

Van Trung Chu

Auto-generated profile, based on publicly available information

Van Trung Chu

Immune Regulation and Cancer, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2016 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
VCVan Trung Chu
Van Trung Chu
TWTimm Weber
Timm Weber
RGRobin Graf
Robin Graf
TSThomas Sommermann
Thomas Sommermann
KPKerstin Petsch
Kerstin Petsch
RKRalf Kuehn
Ralf Kuehn
The CRISPR/Cas9 system is increasingly used for gene inactivation in mouse zygotes, but homology-directed mutagenesis and use of inbred embryos are less established. In particular, Rosa26 knock-in alleles for the insertion of transgenes in a genomic ‘safe harbor’ site, have not been produced. Here we applied CRISPR/Cas9 for the knock-in of 8–11 kb inserts into Rosa26 of C57BL/6 zygotes. We found that 10–20 % of live pups derived from microinjected zygotes were founder mutants, without apparent off-target effects, and up to 50 % knock-in embryos were recovered upon coinjection of Cas9 mRNA and protein. Using this approach, we established a new mouse line for the Cre/loxP-dependent expression of Cas9. Altogether, our protocols and resources support the fast and direct generation of new Rosa26 knock-in alleles and of Cas9-mediated in vivo gene editing in the widely used C57BL/6 inbred strain.

11 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VCVan Trung Chu
Van Trung Chu
RGRobin Graf
Robin Graf
TWTristan Wirtz
Tristan Wirtz
TWTimm Weber
Timm Weber
JFJeremy Favret
Jeremy Favret
KRKlaus Rajewsky
Klaus Rajewsky
Significance: Efficient clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-mediated mutagenesis is necessary for robust genetic screening in primary cells and requires sufficiently high levels of Cas9 and reliable single guide RNAs (sgRNAs). We provide a sgRNA design tool that selects high-fidelity sgRNAs and a Cas9 transgenic mouse line that expresses Cas9 at high levels in all cells analyzed. Using this system, we achieved an average knockout efficiency of 80% in primary B cells and established a robust CRISPR/Cas9-mediated genetic screening system that can be adapted to other primary cell types.

15 February 2019 in Science
Verified
Journal Article
Closed access
PDF file
RGRobin Graf
Robin Graf
JSJane Seagal
Jane Seagal
KOKevin L. Otipoby
Kevin L. Otipoby
KLKong-Peng Lam
Kong-Peng Lam
SASalah Ayoub
Salah Ayoub
KRKlaus Rajewsky
Klaus Rajewsky
B1 or B2? The BCR decides: Immunological B cells are generally divided into two major subsets. B2 cells generate specific antibodies against foreign antigens in secondary lymphoid organs. B1 cells, found predominantly in the peritoneal and pleural cavities, instead produce “natural” antibodies as part of the innate immune system. Two models to explain this split exist: the “lineage model,” wherein both subsets have distinct progenitors, and the “selection model,” in which fates are directed by different B cell antigen receptors (BCRs). Graf et al. provide support for the selection model using a transgenic system in which BCR specificities can be changed. Mature B2 cells differentiated into functional B1 cells when a self-reactive B1 BCR was swapped in, in the absence of B1 lineage precommitment. Science , this issue p. 748

3 June 2022 in Science Advances
Verified
Journal Article
Open access
NTNgoc Tung Tran
Ngoc Tung Tran
EDEric Danner
Eric Danner
XLXun Li
Xun Li
RGRobin Graf
Robin Graf
MLMikhail Lebedin
Mikhail Lebedin
VCVan Trung Chu
Van Trung Chu
While CRISPR-Cas9 is key for the development of gene therapy, its potential off-target mutations are still a major concern. Here, we establish a “spacer-nick” gene correction approach that combines the Cas9 D10A nickase with a pair of PAM-out sgRNAs at a distance of 200 to 350 bp. In combination with adeno-associated virus (AAV) serotype 6 template delivery, our approach led to efficient HDR in human hematopoietic stem and progenitor cells (HSPCs including long-term HSCs) and T cells, with minimal NHEJ-mediated on-target mutations. Using spacer-nick, we developed an approach to repair disease-causing mutations occurring in the HBB , ELANE , IL7R , and PRF1 genes. We achieved gene correction efficiencies of 20 to 50% with minimal NHEJ-mediated on-target mutations. On the basis of in-depth off-target assessment, frequent unintended genetic alterations induced by classical CRISPR-Cas9 were significantly reduced or absent in the HSPCs treated with spacer-nick. Thus, the spacer-nick gene correction approach provides improved safety and suitability for gene therapy.

1 December 2020 in Molecular Therapy
Verified
Journal Article
Open access
NTNgoc Tung Tran
Ngoc Tung Tran
RGRobin Graf
Robin Graf
AWAnnika Wulf-Goldenberg
Annika Wulf-Goldenberg
MSMaria Stecklum
Maria Stecklum
GSGabriele Strauß
Gabriele Strauß
VCVan Trung Chu
Van Trung Chu
Severe congenital neutropenia (SCN) is a monogenic disorder. SCN patients are prone to recurrent life-threatening infections. The main causes of SCN are autosomal dominant mutations in the ELANE gene that lead to a block in neutrophil differentiation. In this study, we use CRISPR-Cas9 ribonucleoproteins and adeno-associated virus (AAV)6 as a donor template delivery system to repair the ELANEL172P mutation in SCN patient-derived hematopoietic stem and progenitor cells (HSPCs). We used a single guide RNA (sgRNA) specifically targeting the mutant allele, and an sgRNA targeting exon 4 of ELANE. Using the latter sgRNA, ∼34% of the known ELANE mutations can in principle be repaired. We achieved gene correction efficiencies of up to 40% (with sgELANE-ex4) and 56% (with sgELANE-L172P) in the SCN patient-derived HSPCs. Gene repair restored neutrophil differentiation in vitro and in vivo upon HSPC transplantation into humanized mice. Mature edited neutrophils expressed normal elastase levels and behaved normally in functional assays. Thus, we provide a proof of principle for using CRISPR-Cas9 to correct ELANE mutations in patient-derived HSPCs, which may translate into gene therapy for SCN.

2 July 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
TLThi Thanh Huong Le
Thi Thanh Huong Le
NTNgoc Tung Tran
Ngoc Tung Tran
TDThi Mai Lan Dao
Thi Mai Lan Dao
DNDinh Dung Nguyen
Dinh Dung Nguyen
HDHuy Duong Do
Huy Duong Do
VCVan Trung Chu
Van Trung Chu
Patients with Rett syndrome (RTT) have severe mental and physical disabilities. The majority of RTT patients carry a heterozygous mutation in methyl-CpG binding protein 2 (MECP2), an X-linked gene encoding an epigenetic factor crucial for normal nerve cell function. No curative therapy for RTT syndrome exists, and cellular mechanisms are incompletely understood. Here, we developed a CRISPR/Cas9-mediated system that targets and corrects the disease relevant regions of the MECP2 exon 4 coding sequence. We achieved homologous recombination (HR) efficiencies of 20% to 30% in human cell lines and iPSCs. Furthermore, we successfully introduced a MECP2R270X mutation into the MECP2 gene in human induced pluripotent stem cells (iPSCs). Consequently, using CRISPR/Cas9, we were able to repair such mutations with high efficiency in human mutant iPSCs. In summary, we provide a new strategy for MECP2 gene targeting that can be potentially translated into gene therapy or for iPSCs-based disease modeling of RTT syndrome.